These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38359166)

  • 1. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
    Liang Y; Gersch CL; Lehman J; Henry NL; Smith KL; Rae JM; Stearns V; Hertz DL
    Pharmacogenet Genomics; 2024 Jun; 34(4):126-129. PubMed ID: 38359166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
    Hertz DL; Douglas JA; Miller RM; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
    Support Care Cancer; 2022 Oct; 30(10):8059-8067. PubMed ID: 35776183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
    Stearns V; Jegede OA; Chang VT; Skaar TC; Berenberg JL; Nand R; Shafqat A; Jacobs NL; Luginbuhl W; Gilman P; Benson AB; Goodman JR; Buchschacher GL; Henry NL; Loprinzi CL; Flynn PJ; Mitchell EP; Fisch MJ; Sparano JA; Wagner LI
    Clin Cancer Res; 2024 Jul; 30(13):2709-2718. PubMed ID: 38640040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
    Hertz DL; Smith KL; Zong Y; Gersch CL; Pesch AM; Lehman J; Blackford AL; Henry NL; Kidwell KM; Rae JM; Stearns V
    Front Genet; 2021; 12():662734. PubMed ID: 34211496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
    Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
    Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
    Henry NL; Pchejetski D; A'Hern R; Nguyen AT; Charles P; Waxman J; Li L; Storniolo AM; Hayes DF; Flockhart DA; Stearns V; Stebbing J
    Br J Cancer; 2010 Jul; 103(3):291-6. PubMed ID: 20606683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
    Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
    Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms.
    Henry NL; Unger JM; Till C; Crew KD; Fisch MJ; Hershman DL
    JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34901744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
    Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
    Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
    Wang J; Lu K; Song Y; Zhao S; Ma W; Xuan Q; Tang D; Zhao H; Liu L; Zhang Q
    PLoS One; 2015; 10(7):e0133964. PubMed ID: 26218592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.
    Peng N; Zhang Y; Ma C; Yu MW; Yang GW; Fu Q; Xu WR; Wang XM
    Trials; 2014 May; 15():171. PubMed ID: 24885324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
    Hack CC; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Almstedt K; Gass P; Heindl F; Brodkorb T; Willer L; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA; Nabieva N
    Breast; 2020 Apr; 50():11-18. PubMed ID: 31958661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
    Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
    Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.